Thoratec long-term opportunity remains intact, says Leerink Leerink believes Thoratec's long-term market opportunity remains intact despite the company's disappointing Q2 results. The firm reiterates an Outperform rating on the stock, but notes shares are likely to be range-bound in the near-term. Leerink lowered it s price target for the name to $35 from $40. Thoratec was downgraded this morning at Credit Suisse and Goldman Sachs.
News For THOR From The Last 14 Days
Check below for free stories on THOR the last two weeks.